Correlation Between Immunovant and Pliant Therapeutics

Can any of the company-specific risk be diversified away by investing in both Immunovant and Pliant Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunovant and Pliant Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immunovant and Pliant Therapeutics, you can compare the effects of market volatilities on Immunovant and Pliant Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunovant with a short position of Pliant Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunovant and Pliant Therapeutics.

Diversification Opportunities for Immunovant and Pliant Therapeutics

0.83

Correlation Coefficient

Immunovant  Pliant Therapeutics

Very poor diversification

The 3 months correlation between Immunovant and Pliant is 0.83. Overlapping area represents the amount of risk that can be diversified away by holding Immunovant and Pliant Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pliant Therapeutics and Immunovant is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunovant are associated (or correlated) with Pliant Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pliant Therapeutics has no effect on the direction of Immunovant i.e., Immunovant and Pliant Therapeutics go up and down completely randomly.

Pair Corralation between Immunovant and Pliant Therapeutics

Given the investment horizon of 90 days Immunovant is expected to generate 1.1 times more return on investment than Pliant Therapeutics. However, Immunovant is 1.1 times more volatile than Pliant Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Pliant Therapeutics is currently generating about -0.06 per unit of risk. If you would invest  1,555  in Immunovant on November 29, 2024 and sell it today you would earn a total of  470.00  from holding Immunovant or generate 30.23% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Immunovant  vs.  Pliant Therapeutics

Immunovant

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pliant Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pliant Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Immunovant and Pliant Therapeutics

The main advantage of trading using opposite Immunovant and Pliant Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunovant position performs unexpectedly, Pliant Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pliant Therapeutics will offset losses from the drop in Pliant Therapeutics' long position.

The idea behind Immunovant and Pliant Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.